Caspase-8/c-FLIPL Dimerization Activators for Enhanced Cancer-Cell Apoptosis
Solution Overview
Problem
Current cancer therapies face challenges in effectively targeting the caspase-8/c-FLIP interaction for enhancing apoptosis in cancer cells due to resistance and inefficiencies in existing approaches, necessitating the development of new strategies to modulate this interaction for improved therapeutic outcomes.
Innovation Solution
Design and identification of small molecules that stabilize the caspase-8/c-FLIP heterodimer by mimicking the 'closed' conformation of the L2' loop, enhancing caspase-8 activity at the DISC and promoting apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cancer therapies target the caspase-8/c-FLIP interaction, then apoptosis induction is improved, but resistance and inefficiency occur due to the stability of the heterodimer complex
Solution Approach 1:
The patent applies preliminary action by using small molecules to pre-stabilize the caspase-8/c-FLIPL heterodimer in a 'closed' conformation before apoptotic signaling is fully activated. This pre-stabilization ensures that caspase-8 is primed and ready for activation, making the cancer cells more susceptible to apoptosis-inducing therapies and overcoming resistance mechanisms.
Solution Approach 2:
The patent employs parameter changes by modifying the conformational state of the caspase-8/c-FLIPL heterodimer from an 'open' to a 'closed' state through small molecule binding. This conformational parameter change increases caspase-8 activity and stabilizes the complex, thereby enhancing apoptosis induction efficacy and overcoming therapeutic resistance.
2Productivity
If small molecules are designed to stabilize the caspase-8/c-FLIP heterodimer, then caspase-8 activity is enhanced, but the complexity of drug design increases
Solution Approach 1:
The patent uses small molecules as intermediaries that bind to the caspase-8/c-FLIPL heterodimer interface to stabilize the complex and enhance caspase-8 activity. These small molecules act as mediators between the therapeutic goal (enhancing apoptosis) and the molecular target (caspase-8/c-FLIPL interaction), providing a simplified approach compared to designing large biologic agents.
Solution Approach 2:
The patent applies copying by designing small molecules that mimic or replicate the stabilizing interactions naturally occurring in the active caspase-8/c-FLIPL complex. By copying the essential stabilizing features into small molecule structures, the patent achieves high caspase-8 activity enhancement with simpler, more drug-like compounds rather than complex biologics.
Data Source
AI summary
The present invention relates to activators of caspase-8/c-FLIPL dimerization and their use in enhancing the pro-apoptotic activity of the heterodimer and cancer therapy.